213 related articles for article (PubMed ID: 35145077)
1. Deciphering spatial genomic heterogeneity at a single cell resolution in multiple myeloma.
Merz M; Merz AMA; Wang J; Wei L; Hu Q; Hutson N; Rondeau C; Celotto K; Belal A; Alberico R; Block AW; Mohammadpour H; Wallace PK; Tario J; Luce J; Glenn ST; Singh P; Herr MM; Hahn T; Samur M; Munshi N; Liu S; McCarthy PL; Hillengass J
Nat Commun; 2022 Feb; 13(1):807. PubMed ID: 35145077
[TBL] [Abstract][Full Text] [Related]
2. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma.
Tian E; Zhan F; Walker R; Rasmussen E; Ma Y; Barlogie B; Shaughnessy JD
N Engl J Med; 2003 Dec; 349(26):2483-94. PubMed ID: 14695408
[TBL] [Abstract][Full Text] [Related]
3. Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease.
Garcia-Gomez A; De Las Rivas J; Ocio EM; Díaz-Rodríguez E; Montero JC; Martín M; Blanco JF; Sanchez-Guijo FM; Pandiella A; San Miguel JF; Garayoa M
Oncotarget; 2014 Sep; 5(18):8284-305. PubMed ID: 25268740
[TBL] [Abstract][Full Text] [Related]
4. Single-cell RNA-seq reveals clonal diversity and prognostic genes of relapsed multiple myeloma.
He H; Li Z; Lu J; Qiang W; Jiang S; Xu Y; Fu W; Zhai X; Zhou L; Qian M; Du J
Clin Transl Med; 2022 Mar; 12(3):e757. PubMed ID: 35297204
[TBL] [Abstract][Full Text] [Related]
5. Enrichment-Free Single-Cell Detection and Morphogenomic Profiling of Myeloma Patient Samples to Delineate Circulating Rare Plasma Cell Clones.
Ndacayisaba LJ; Rappard KE; Shishido SN; Ruiz Velasco C; Matsumoto N; Navarez R; Tang G; Lin P; Setayesh SM; Naghdloo A; Hsu CJ; Maney C; Symer D; Bethel K; Kelly K; Merchant A; Orlowski R; Hicks J; Mason J; Manasanch EE; Kuhn P
Curr Oncol; 2022 Apr; 29(5):2954-2972. PubMed ID: 35621632
[TBL] [Abstract][Full Text] [Related]
6. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing.
Rasche L; Chavan SS; Stephens OW; Patel PH; Tytarenko R; Ashby C; Bauer M; Stein C; Deshpande S; Wardell C; Buzder T; Molnar G; Zangari M; van Rhee F; Thanendrarajan S; Schinke C; Epstein J; Davies FE; Walker BA; Meissner T; Barlogie B; Morgan GJ; Weinhold N
Nat Commun; 2017 Aug; 8(1):268. PubMed ID: 28814763
[TBL] [Abstract][Full Text] [Related]
7. Hepatocyte growth factor pathway upregulation in the bone marrow microenvironment in multiple myeloma is associated with lytic bone disease.
Kristensen IB; Christensen JH; Lyng MB; Møller MB; Pedersen L; Rasmussen LM; Ditzel HJ; Abildgaard N
Br J Haematol; 2013 May; 161(3):373-82. PubMed ID: 23431957
[TBL] [Abstract][Full Text] [Related]
8. AngioMap is a novel image analysis algorithm for assessment of plasma cell distribution within bone marrow vascular niche.
Salama ME; Lange H; Tripp SR; Kohan J; Landis ND; Krueger JS; Potts SJ
Appl Immunohistochem Mol Morphol; 2014 Aug; 22(7):550-4. PubMed ID: 23958550
[TBL] [Abstract][Full Text] [Related]
9. Differentiation stage of myeloma plasma cells: biological and clinical significance.
Paiva B; Puig N; Cedena MT; de Jong BG; Ruiz Y; Rapado I; Martinez-Lopez J; Cordon L; Alignani D; Delgado JA; van Zelm MC; Van Dongen JJ; Pascual M; Agirre X; Prosper F; Martín-Subero JI; Vidriales MB; Gutierrez NC; Hernandez MT; Oriol A; Echeveste MA; Gonzalez Y; Johnson SK; Epstein J; Barlogie B; Morgan GJ; Orfao A; Blade J; Mateos MV; Lahuerta JJ; San-Miguel JF
Leukemia; 2017 Feb; 31(2):382-392. PubMed ID: 27479184
[TBL] [Abstract][Full Text] [Related]
10. Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients.
Zannettino AC; Farrugia AN; Kortesidis A; Manavis J; To LB; Martin SK; Diamond P; Tamamura H; Lapidot T; Fujii N; Gronthos S
Cancer Res; 2005 Mar; 65(5):1700-9. PubMed ID: 15753365
[TBL] [Abstract][Full Text] [Related]
11. Dickkopf-related protein 1 expression in bone marrow of multiple myeloma patients: correlation with bone disease and plasma cell malignancy type.
Auziņa D; Beinaroviča I; Janicka-Kupra B; Lejniece S; Lejnieks A; Groma V
Exp Oncol; 2020 Dec; 42(4):285-288. PubMed ID: 33355872
[TBL] [Abstract][Full Text] [Related]
12. Quantification of bone marrow plasma cell infiltration in multiple myeloma: usefulness of bone marrow aspirate clot with CD138 immunohistochemistry.
Matsue K; Matsue Y; Kumata K; Usui Y; Suehara Y; Fukumoto K; Fujisawa M; Narita K; Takeuchi M
Hematol Oncol; 2017 Sep; 35(3):323-328. PubMed ID: 27140172
[TBL] [Abstract][Full Text] [Related]
13. Sclerostin is overexpressed by plasma cells from multiple myeloma patients.
Brunetti G; Oranger A; Mori G; Specchia G; Rinaldi E; Curci P; Zallone A; Rizzi R; Grano M; Colucci S
Ann N Y Acad Sci; 2011 Nov; 1237():19-23. PubMed ID: 22082361
[TBL] [Abstract][Full Text] [Related]
14. Morphologic and cytogenetic variables affect the flow cytometric recovery of plasma cell myeloma cells in bone marrow aspirates.
Cogbill CH; Spears MD; Vantuinen P; Harrington AM; Olteanu H; Kroft SH
Int J Lab Hematol; 2015 Dec; 37(6):797-808. PubMed ID: 26224420
[TBL] [Abstract][Full Text] [Related]
15. Upregulation of Syndecan-1 in the bone marrow microenvironment in multiple myeloma is associated with angiogenesis.
Andersen NF; Kristensen IB; Preiss BS; Christensen JH; Abildgaard N
Eur J Haematol; 2015 Sep; 95(3):211-7. PubMed ID: 25353275
[TBL] [Abstract][Full Text] [Related]
16. Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma.
Ledergor G; Weiner A; Zada M; Wang SY; Cohen YC; Gatt ME; Snir N; Magen H; Koren-Michowitz M; Herzog-Tzarfati K; Keren-Shaul H; Bornstein C; Rotkopf R; Yofe I; David E; Yellapantula V; Kay S; Salai M; Ben Yehuda D; Nagler A; Shvidel L; Orr-Urtreger A; Halpern KB; Itzkovitz S; Landgren O; San-Miguel J; Paiva B; Keats JJ; Papaemmanuil E; Avivi I; Barbash GI; Tanay A; Amit I
Nat Med; 2018 Dec; 24(12):1867-1876. PubMed ID: 30523328
[TBL] [Abstract][Full Text] [Related]
17. The Y-box binding protein YB-1 is associated with progressive disease and mediates survival and drug resistance in multiple myeloma.
Chatterjee M; Rancso C; Stühmer T; Eckstein N; Andrulis M; Gerecke C; Lorentz H; Royer HD; Bargou RC
Blood; 2008 Apr; 111(7):3714-22. PubMed ID: 18006704
[TBL] [Abstract][Full Text] [Related]
18. Dickkopf-1 is a key regulator of myeloma bone disease: opportunities and challenges for therapeutic intervention.
Zhou F; Meng S; Song H; Claret FX
Blood Rev; 2013 Nov; 27(6):261-7. PubMed ID: 24054128
[TBL] [Abstract][Full Text] [Related]
19. Genetic interrogation of circulating multiple myeloma cells at single-cell resolution.
Lohr JG; Kim S; Gould J; Knoechel B; Drier Y; Cotton MJ; Gray D; Birrer N; Wong B; Ha G; Zhang CZ; Guo G; Meyerson M; Yee AJ; Boehm JS; Raje N; Golub TR
Sci Transl Med; 2016 Nov; 8(363):363ra147. PubMed ID: 27807282
[TBL] [Abstract][Full Text] [Related]
20. Automated and simplified identification of normal and abnormal plasma cells in Multiple Myeloma by flow cytometry.
Alaterre E; Raimbault S; Garcia JM; Rème T; Requirand G; Klein B; Moreaux J
Cytometry B Clin Cytom; 2018 May; 94(3):484-492. PubMed ID: 28865180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
